600566.SHG Hubei Jumpcan Pharmaceutical Co Ltd
- Market cap
- CNY 26.8B
- P/E
- 14.7x
- P/B
- 1.88x
- ROE
- 10.0%
- Dividend yield
- 7.20%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600566.SHG undervalued?
Graham number600566.SHG trades 10.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hubei Jumpcan Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Hubei Jumpcan Pharmaceutical Co Ltd yet.
Hubei Jumpcan Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of medicines in China. The company offers drugs in the fields of pediatrics, respiratory system, digestive system, and gynecology. It is also involved in daily chemical product sales; and wholesale and retail pharmaceuticals. The company is headquartered in Taixing, China.
Full company profileHubei Jumpcan Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hubei Jumpcan Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.68B | 5.64B | 7.21B | 6.94B | 6.16B | 7.63B | 9.00B | 9.65B | 8.02B | 6.22B | 4.85B |
| Gross Profit | 3.99B | 4.79B | 6.11B | 5.83B | 5.03B | 6.35B | 7.46B | 7.87B | 6.35B | 4.91B | 3.87B |
| Operating Income | 1.06B | 1.37B | 1.90B | 1.86B | 1.47B | 1.93B | 2.42B | 3.26B | 2.86B | 1.88B | 1.36B |
| EBITDA | 1.16B | 1.50B | 2.04B | 2.04B | 1.67B | 1.96B | 2.56B | 3.18B | 2.73B | 2.48B | 1.67B |
| Net Income | 934M | 1.22B | 1.69B | 1.62B | 1.28B | 1.72B | 2.17B | 2.82B | 2.53B | 1.78B | 1.41B |
| EPS | 1.17 | 1.51 | 2.07 | 1.99 | 1.53 | 1.91 | 2.39 | 3.08 | 2.76 | 1.93 | 1.53 |
| Balance Sheet | |||||||||||
| Total Assets | 4.99B | 6.66B | 7.80B | 8.66B | 10.5B | 12.1B | 15.0B | 18.1B | 18.5B | 17.7B | 17.1B |
| Total Liabilities | 1.30B | 2.26B | 2.34B | 2.56B | 2.75B | 3.00B | 3.63B | 4.77B | 3.73B | 3.07B | 2.99B |
| Shareholders' Equity | 3.66B | 4.40B | 5.46B | 6.10B | 7.76B | 9.12B | 11.3B | 13.3B | 14.7B | 14.6B | 14.1B |
| Cash & Short-term Investments | 890M | 952M | 1.59B | 2.47B | 4.22B | 5.49B | 7.86B | 10.9B | 11.8B | 5.44B | 3.86B |
| Total Debt | 84.9M | 698M | 553M | 577M | 604M | 630M | 401M | 1.04B | 788M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 913M | 1.19B | 1.71B | 2.15B | 1.78B | 1.89B | 2.62B | 3.46B | 2.18B | 1.20B | - |
| Capital Expenditure | 323M | 746M | 668M | 546M | 430M | 248M | 244M | 302M | 174M | 95.9M | 314M |
| Free Cash Flow | 590M | 443M | 1.04B | 1.60B | 1.35B | 1.65B | 2.38B | 3.16B | 2.00B | 1.10B | 1.01B |
| Ratios | |||||||||||
| ROE | 25.5% | 27.8% | 30.9% | 26.6% | 16.5% | 18.9% | 19.1% | 21.1% | 17.2% | 12.2% | 10.0% |
| ROA | 18.7% | 18.4% | 21.6% | 18.7% | 12.1% | 14.2% | 14.5% | 15.6% | 13.7% | 10.0% | 8.3% |
| Net Profit Margin | 20.0% | 21.7% | 23.4% | 23.4% | 20.7% | 22.5% | 24.1% | 29.2% | 31.6% | 28.6% | 29.2% |
| Debt to Equity | 0.02x | 0.16x | 0.10x | 0.09x | 0.08x | 0.07x | 0.04x | 0.08x | 0.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hubei Jumpcan Pharmaceutical Co Ltd dividends
- Dividend yield
- 7.20%
- Forward dividend
- 1.74 CNY
- Payout ratio
- 108.5%
- Ex-dividend date
- Jun 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.93B | 2.09 | 108.5% |
| 2024 | CNY 1.20B | 1.30 | 47.2% |
| 2023 | CNY 811M | 0.89 | 28.7% |
| 2022 | CNY 604M | 0.67 | 27.8% |
| 2021 | CNY 400M | 0.44 | 23.3% |
| 2020 | CNY 1.00B | 1.20 | 78.5% |
| 2019 | CNY 1.00B | 1.23 | 61.8% |
| 2018 | CNY 811M | 0.99 | 48.0% |
| 2017 | CNY 591M | 0.73 | 48.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 18, 2010.
Who owns Hubei Jumpcan Pharmaceutical Co Ltd
- Insiders 62.46%
- Institutions 9.46%
- Public & others 28.09%
- Shares outstanding 922M
- Free float 345M
Hubei Jumpcan Pharmaceutical Co Ltd company profile
- Company name
- Hubei Jumpcan Pharmaceutical Co Ltd
- Ticker
- 600566.SHG
- ISIN
- CNE0000018X6
- Exchange
- Shanghai Stock Exchange
- Listed since
- Aug 1, 2001
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,137
- Fiscal year end
- December
- Address
- Baotawan, Taixing, China, 225441
- Phone
- 86 40 0118 9696
- Website
- jumpcan.com
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of medicines in China. The company offers drugs in the fields of pediatrics, respiratory system, digestive system, and gynecology. It is also involved in daily chemical product sales; and wholesale and retail pharmaceuticals. The company is headquartered in Taixing, China.
Hubei Jumpcan Pharmaceutical Co Ltd management
6- Mr. Fei CaoVice Chairman & GM · born 1983
- Mr. Hong Quan YanDeputy GM & Financial Director · born 1968
- Mr. Wen Zheng ShiDirector of Human Resources · born 1979
- Mr. Wei CaoDeputy GM, Board Secretary & Director · born 1987
- Mr. Qu Rong HuangEmployee Representative Director · born 1962
- Jian Hong XiAccounting Supervisor